Moleculin Biotech (MBRX)
(Delayed Data from NSDQ)
$5.02 USD
-0.13 (-2.52%)
Updated May 3, 2024 03:59 PM ET
After-Market: $5.38 +0.36 (7.17%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth F Momentum D VGM
Brokerage Reports
0 items in cart
Moleculin Biotech, Inc. [MBRX]
Reports for Purchase
Showing records 61 - 80 ( 159 total )
Company: Moleculin Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Moleculin Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Moleculin Biotech, Inc.
Industry: Medical - Biomedical and Genetics
3Q21: Full Clinical Trial Plate, Solid Annamycin Data, Well-Funded to 2024
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Moleculin Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Moleculin Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Highly Encouraging Interim Phase 1b Annamycin Results in STS-LM Patients
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Moleculin Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Moleculin Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Moleculin Biotech, Inc.
Industry: Medical - Biomedical and Genetics
STS/LM Trial Cohort 1 Dose Shows Highly Favorable Safety Profile
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Moleculin Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Moleculin Biotech, Inc.
Industry: Medical - Biomedical and Genetics
2Q21: Expanding Clinical Pipeline, Well-Funded at Least Through 2023
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Moleculin Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Moleculin Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Allowed to Extend Dose Escalation in E.U. Phase 1/2 Annamycin AML Trial
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Moleculin Biotech, Inc.
Industry: Medical - Biomedical and Genetics
1Q21: Expanding Clinical Pipeline, Well-Funded at Least Through 2023
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Moleculin Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Moleculin Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Moleculin Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Gets 4th Rare Pediatric Disease Designation for WP1066, 4 Potential PRVs
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Moleculin Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Moleculin Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Annamycin Receives Fast Track in STS-LM, Recently Amended WPD Agreement
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Moleculin Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Moleculin Biotech, Inc.
Industry: Medical - Biomedical and Genetics
4Q20: Annamycin Combo AML Trial, Monotherapy in STS-LM, Very Well Funded
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J